Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
May 19, 2026
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
May 18, 2026
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
May 18, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2026
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
May 16, 2026